BioRender was last valued at $900M (post-money). It comes from the Strategic Investment / Employee Liquidity of Dec 2025. The company is private, so there is no listed share price.
1 valuation. The latest, $900M post-money, was set by the Strategic Investment / Employee Liquidity in Dec 2025.
A private valuation is the price agreed in one transaction. The BioRender valuation of $900M is a post-money figure from the Strategic Investment / Employee Liquidity dated 18 Dec 2025 .
The valuation holds until the next priced round or secondary sale. A private company founded in 2017 with roughly 100 people has no daily price and no order book between rounds.
The closest scientific visualization software peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. BioRender is a private company; its shares do not trade on a public exchange.
The last valuation is $900M (post-money, Dec 2025).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
